Evidence map›Paper›PMID 38527452›Full record

ArticleJournal of innate immunity2024

Type I Interferon, Induced by Adenovirus or Adenoviral Vector Infection, Regulates the Cytokine Response to Lipopolysaccharide in a Macrophage Type-Specific Manner.

Mareike D Maler, Sophie Zwick, Carsten Kallfass, Peggy Engelhard, Hexin Shi, Laura Hellig, Pang Zhengyang, Annika Hardt, Gernot Zissel, Zsolt Ruzsics and 10 more

Open access · goldAbstract read
In one paragraph

Article in Journal of innate immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Mareike D MalerMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Sophie ZwickDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Carsten KallfassInstitute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Peggy EngelhardDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Hexin ShiCenter for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Laura HelligDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Pang ZhengyangFaculty of Biology, University of Freiburg, Freiburg, Germany.
Annika HardtDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Gernot ZisselDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Zsolt RuzsicsInstitute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Willi Jahnen-DechentSignalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Stefan F MartinAllergy Research Group, Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Peter Jess NielsenMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Daiana StolzDepartment of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Justyna LopateckaHelmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Faculty of Medicine, Aachen, Germany.
Sarah BastyansHelmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Faculty of Medicine, Aachen, Germany.
Bruce BeutlerCenter for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Wolfgang W SchamelFaculty of Biology, University of Freiburg, Freiburg, Germany.
György FejerMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Marina Alexandra FreudenbergMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Max Planck Institute of Immunobiology and Epigenetics · DEUniversity of Freiburg · DEThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile TLR ligands derived from microbial flora and pathogens are important activators of the innate immune system, a variety of factors such as intracellular bacteria, viruses, and parasites can induce a state of hyperreactivity, causing a dysregulated and potentially life-threatening cytokine over-response upon TLR ligand exposure. Type I interferon (IFN-αβ) is a central mediator in the induction of hypersensitivity and is strongly expressed in splenic conventional dendritic cells (cDC) and marginal zone macrophages (MZM) when mice are infected with adenovirus. This study investigates the ability of adenoviral infection to influence the activation state of the immune system and underlines the importance of considering this state when planning the treatment of patients.

methodsInfection with adenovirus-based vectors (Ad) or pretreatment with recombinant IFN-β was used as a model to study hypersensitivity to lipopolysaccharide (LPS) in mice, murine macrophages, and human blood samples. The TNF-α, IL-6, IFN-αβ, and IL-10 responses induced by LPS after pretreatment were measured. Mouse knockout models for MARCO, IFN-αβR, CD14, IRF3, and IRF7 were used to probe the mechanisms of the hypersensitive reaction.

resultsWe show that, similar to TNF-α and IL-6 but not IL-10, the induction of IFN-αβ by LPS increases strongly after Ad infection. This is true both in mice and in human blood samples ex vivo, suggesting that the regulatory mechanisms seen in the mouse are also present in humans. In mice, the scavenger receptor MARCO on IFN-αβ-producing cDC and splenic marginal zone macrophages is important for Ad uptake and subsequent cytokine overproduction by LPS. Interestingly, not all IFN-αβ-pretreated macrophage types exposed to LPS exhibit an enhanced TNF-α and IL-6 response. Pretreated alveolar macrophages and alveolar macrophage-like murine cell lines (MPI cells) show enhanced responses, while bone marrow-derived and peritoneal macrophages show a weaker response. This correlates with the respective absence or presence of the anti-inflammatory IL-10 response in these different macrophage types. In contrast, Ad or IFN-β pretreatment enhances the subsequent induction of IFN-αβ in all macrophage types. IRF3 is dispensable for the LPS-induced IFN-αβ overproduction in infected MPI cells and partly dispensable in infected mice, while IRF7 is required. The expression of the LPS co-receptor CD14 is important but not absolutely required for the elicitation of a TNF-α over-response to LPS in Ad-infected mice.

conclusionViral infections or application of virus-based vaccines induces type I interferon and can tip the balance of the innate immune system in the direction of hyperreactivity to a subsequent exposure to TLR ligands. The adenoviral model presented here is one example of how multiple factors, both environmental and genetic, affect the physiological responses to pathogens. Being able to measure the current reactivity state of the immune system would have important benefits for infection-specific therapies and for the prevention of vaccination-elicited adverse effects.

Indexed as

AdenoviridaeCytokinesInterferon Regulatory Factor-3LipopolysaccharidesMacrophagesMice, KnockoutAdenoviridae InfectionsAnimalsCells, CulturedDendritic CellsGenetic VectorsHumansInterferon-betaInterferon Regulatory Factor-7Interferon Type ILipopolysaccharide ReceptorsCytokinesInterferon-betaInterferon Regulatory Factor-3Interferon Regulatory Factor-7Interferon Type IIrf3 protein, mouseIrf7 protein, mouseLipopolysaccharide ReceptorsLipopolysaccharidesReceptor, Interferon alpha-betaAdenoviral vectorCytokinesIFN-αβLipopolysaccharideMacrophages

Identifiers

PMID38527452
PMCPMC11023693
OpenAlexW4393163643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.